CMHC Exhibitor Showcase

Akcea Therapeutics

Akcea Therapeutics

Address: 55 Cambridge Parkway Suite 100, Cambridge, MA 02142

Phone: 617-207-0280

Email: vsalvatore@akceatx.com

Website: www.akceatx.com

Booth #: 324

Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders. Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea's portfolio spans multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea's investigational pipeline includes novel drugs designed to reduce several lipid risk factors, including LDL-Cholesterol, apoC-III, triglycerides and Lp(a). Volanesorsen, Akcea's most advanced investigational drug, is in Phase 3 trials for ultra-orphan lipid disorders characterized by extremely high triglycerides and apoC-III, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL).

BACK